PRINCIPLE LABS LLC NPI 1346648870

NPI Details

PRINCIPLE LABS LLC is a clinical medical laboratory in Bethlehem, PA. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. PRINCIPLE LABS LLC NPI is 1346648870. The provider is registered as an organization entity type.

The provider's business location address is:

2550 BRODHEAD RD
SUITE 105
BETHLEHEM, PA
ZIP 18020-922
Phone: (484) 353-6661
Fax: (484) 353-6663

The provider's authorized official is Jason Polete .
The authorized official title is Coo and has the following contact phone number (484) 353-6661.

The CLIA number assigned to this NPI record is 21D2162856 - physician office with a certificate type of Certificate of Waiver.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0004)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0480)
• Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique (HCPCS:87491)
• Detection of mycoplasma genitalium by dna or rna probe (HCPCS:87563)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique (HCPCS:87641)
• Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique (HCPCS:87500)
• Detection test by nucleic acid for herpes simplex virus, amplified probe technique (HCPCS:87529)
• Detection test by nucleic acid for multiple organisms, amplified probe(s) technique (HCPCS:87801)
• Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique (HCPCS:87591)
• Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique (HCPCS:87661)
• Detection test by nucleic acid for human papillomavirus (hpv), types 16 and 18 only (HCPCS:87625)
• Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets (HCPCS:87631)
• Gene analysis (cytochrome p450, family 2, subfamily d, polypeptide 6) common variants (HCPCS:81226)
• Gene analysis (cytochrome p450, family 2, subfamily c, polypeptide 19) common variants (HCPCS:81225)
• Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 12-25 targets (HCPCS:87507)
• Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique (HCPCS:87651)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
• Measurement of dna of bacteria in vaginal fluid specimen (HCPCS:81514)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)

The enumeration date for this NPI number is 12/16/2014 and was last updated on 12/16/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: